A regulatory strategy for clinical development provides the framework for aligning scientific decisions, evidence generation, regulatory expectations and operational execution throughout a development programme. Its value lies in anticipating how choices made today may affect the evidence required at later stages, rather than responding to regulatory questions only when a submission or major clinical milestone approaches.
Table of Contents
Clinical development programmes depend on the alignment of multiple workstreams and on the timing of decisions made across them. As the programme advances, early assumptions become embedded in later studies, making inconsistencies or unresolved dependencies progressively harder to correct.
A robust regulatory strategy therefore needs to evolve alongside the product and remain connected to the broader clinical development pathway.
Why a regulatory strategy for clinical development should start before critical decisions are made
Regulatory considerations begin to influence a programme long before confirmatory trials or marketing authorisation. In early clinical development, several choices remain open to revision. In practice, however, decisions made at this stage can affect the evidence available later and gradually constrain the range of viable development options.
This is particularly relevant when defining:
- Dose selection and escalation strategy;
- Endpoints and outcome measures;
- Patient populations and inclusion criteria;
- The scale and duration of safety exposure.
Regulators assess these elements within the context of the wider development programme. Clinical evidence is considered alongside clinical pharmacology, non-clinical findings, product quality and the overall rationale supporting progression from one stage to the next. Guidance from the Food and Drug Administration (FDA), for example, identifies trial design, dose selection, endpoints, safety, pharmacokinetics, non-clinical evidence and product quality among the areas on which sponsors may seek advice.
For this reason, a regulatory strategy for clinical development should be established early enough to inform critical decisions before key aspects of the programme become difficult to change. It should identify the assumptions that require validation and clarify what evidence will be needed to support subsequent development stages.
7 common mistakes in a regulatory strategy for clinical development
Regulatory problems detected in later development are not necessarily created at that stage. They may reflect a series of earlier choices that were individually reasonable but insufficiently connected to the overall path towards approval. Reviewing these decisions through a regulatory lens can therefore help sponsors identify risks before the available options become more limited.
1. Treating regulatory strategy for clinical development as a submission exercise
Regulatory strategy should not begin only when a formal submission is being prepared, whether an Investigational New Drug (IND) application, clinical trial application (CTA) or a later marketing authorisation application. In each case, earlier development choices may already have shaped the available evidence and reduced the scope for adjustment.
Bringing regulatory considerations into the programme earlier allows teams to assess whether current decisions support later development stages and whether emerging evidence is likely to meet future regulatory needs.
2. Planning individual trials without a coherent development pathway
A well-designed trial does not automatically strengthen the development programme as a whole. Problems arise when studies are planned primarily around the next milestone without a clear view of how their results will inform subsequent decisions.
A regulatory strategy for clinical development should give each study a defined purpose within the wider evidence pathway. The clinical development plan can support this by connecting study design with future milestones, endpoint strategy, statistical planning and decision criteria, while remaining flexible enough to incorporate new evidence.
3. Misaligning clinical design with future evidence requirements
Dose selection, endpoints, comparators and patient populations can all affect the regulatory value of a study. A design that addresses an early scientific question may still leave evidence gaps that become harder to resolve later. These decisions should therefore be assessed against the requirements of subsequent development stages, particularly where they may affect the demonstration of benefit and risk.
4. Disconnecting clinical strategy from non-clinical, CMC and other development functions
Clinical progression depends on evidence generated beyond the clinical protocol itself. Before a programme advances, the supporting package may need to demonstrate that:
- Non-clinical data support the proposed human exposure;
- Clinical pharmacology informs dose and population decisions;
- The investigational product is adequately characterised and controlled;
- Manufacturing activities can support the requirements of the planned clinical stage.
A regulatory strategy for clinical development should map these dependencies against major development milestones and define what evidence must be available before progression. This reduces the risk of clinical plans advancing ahead of the supporting non-clinical, CMC and clinical pharmacology evidence.
5. Approaching regulatory interactions without clear decision questions
Regulatory meetings are most useful when they address a specific development uncertainty. Broad requests for validation can produce less actionable feedback than questions built around a clearly defined issue and the evidence needed to assess the available options.
Sponsors should prepare regulatory interactions around the decisions that require external input. Questions should be specific enough to generate feedback that can be translated into a clear development choice.
6. Underestimating how trial execution can become regulatory risk
Operational weaknesses can affect the regulatory interpretation of clinical evidence. Protocol feasibility, consistency across sites, reliability of outcome measures and the completeness of the resulting data all influence how robustly a study can support its intended conclusions.
A regulatory strategy for clinical development should therefore account for operational feasibility early enough to ensure that the planned evidence can be generated consistently in practice.
7. Treating regulatory strategy as a static plan
New clinical data, safety findings, scientific evidence or regulatory changes can alter assumptions made earlier in development. The strategy should be reviewed at key decision points to ensure that development choices remain aligned with the latest evidence and regulatory context.
Supporting regulatory strategy for clinical development from planning to clinical execution
A regulatory strategy for clinical development is most useful when it remains connected to the scientific and operational realities of the programme. This requires a clear view of the development pathway, particularly where clinical progression depends on non-clinical evidence, CMC readiness, specialised study designs or regulatory interactions at critical milestones.
VectorB2B supports biotechnology and pharmaceutical companies across non-clinical development, regulatory planning, CMC and clinical services. Bringing these capabilities together helps anticipate technical dependencies, prepare regulatory interactions around specific development decisions, coordinate evidence requirements across workstreams and maintain alignment as the programme moves from planning into execution.
Contact our team to discuss your regulatory strategy for clinical development.
Frequently asked questions (FAQ)
1. What is the difference between a regulatory strategy and a clinical development plan (CDP)?
A regulatory strategy defines the approach to regulatory requirements, authority interactions and key regulatory decisions throughout development. A CDP provides the broader clinical development roadmap, integrating planned studies, milestones, endpoints, statistical considerations, development scenarios and relevant regulatory considerations. The two should therefore evolve in close alignment.
2. What should be included in a regulatory authority briefing package?
The content will vary depending on the authority and the stage of development. A briefing package should clearly explain the product and the issue under discussion, while providing the evidence needed to support focused regulatory feedback.
3. How can regulatory intelligence support clinical development decisions?
Regulatory intelligence brings together applicable guidance, relevant precedents, comparable development programmes and previous authority decisions to inform strategic choices. Used early, it can help anticipate regulatory issues and compare possible pathways. It can also indicate where direct authority engagement may be needed. The strategy should nevertheless remain grounded in the characteristics and evidence of the individual product.
